Informação sobre produto
- Letermovir,4-Quinazolineacetic acid
- 8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-
- (4S)-
- (4S)-8-Fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetic acid
- AIC 246
- Prevymis
- (S)-2-(8-Fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic acid
- 4-Quinazolineacetic acid, 8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-, (4S)-
- Aic 246
Applications Letermovir acts as an orally or i.v administered cytomegalovirus terminus complex inhibitor, antiviral agent, used in the treatment of CMV infection which is prevalent in those with immunocompromised systems.
References Kropeit, D. et al.: Brit. J. Clin Pharmacol., 83, 2678 (2017); Kim, E. et al.: Drugs. 78, 147 (2018);
Propriedades químicas
Consulta técnica sobre: TR-L321005 Letermovir
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.